NovaBay Pharmaceuticals to Present at 29th Annual ROTH Conference

By March 7, 2017

EMERYVILLE, Calif. (March 7, 2017) – NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that Chief Financial Officer Tom Paulson is scheduled to present a corporate overview at the 29th Annual ROTH Conference on Tuesday, March 14, 2017, at 3:30 p.m. Pacific time (6:30 p.m. Eastern time).  The conference is being held at The Ritz-Carlton, Laguna Niguel in Dana Point, Calif.

A live webcast and replay will be available on the Investors section of the Company’s website at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
Avenova is formulated with Neutrox®, which is cleared by the U.S. Food and Drug Administration (FDA) as a 510(k) medical device.  Neutrox is NovaBay’s commercial name for its proprietary pure hypochlorous acid.  Data from a multicenter clinical study show that Avenova reduced bacterial load, the underlying cause of blepharitis, on ocular skin surface by more than 90%.  Laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and also neutralizes bacterial toxins.  Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct salesforce.  It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen.

 

Stay informed on NovaBay’s progress:

Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website

NovaBay Contacts

For NovaBay Avenova purchasing information:
Please call us toll Free: 1-800-890-0329 or Email us
www.avenova.com

From the Company
Thomas J. Paulson
Chief Financial Officer
510-899-8809
Contact Tom

Investor Contact
LHA
Jody Cain
310-691-7100
jcain@lhai.com

TOP